Latest Breaking News On - Jenniferk litton - Page 1 : comparemela.com

Pre-Surgery Durvalumab & Tremelimumab Use in HR+/HER2-Negative Breast Cancer

Pre-Surgery Durvalumab & Tremelimumab Use in HR+/HER2-Negative Breast Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesR garber sreyashi basuBeatrize adradaSonali jindalElizabetha mittendorfJenniferk littonKhoi chuAkshara singareeka raghavendraPadmanee sharmaHarvard medical schoolDana farber brigham cancer centerUniversity of texas md anderson cancer centerOncotarget volumeSreyashi basuClinton yamLumarie santiago

Durvalumab and Tremelimumab before surgery in patients with HR+/HER2-negative breast cancer

Durvalumab and Tremelimumab before surgery in patients with HR+/HER2-negative breast cancer
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United statesJenniferk littonBeatrize adradaR garber sreyashi basuAkshara singareeka raghavendraElizabetha mittendorfSonali jindalKhoi chuPadmanee sharmaDana farber brigham cancer centerHarvard medical schoolUniversity of texas md anderson cancer centerSreyashi basuClinton yamLumarie santiagoCancer center

Women Can Safely Interrupt Endocrine Tx to Pursue Pregnancy

Interrupting endocrine therapy may allow three quarters of women with hormone receptor positive breast cancer to achieve pregnancy, while having no impact on their short-term outcomes, new data suggest.

New yorkUnited statesDana farber cancer instituteAnn partridgeJenniferk littonMarleeni meyersUniversity of texas md anderson cancer centerInternational breast cancer study groupPartners foundationAlliance for clinical trials in oncologyHarvard medical schoolLangone perlmutter cancer centerBreast international groupClinical researchSan antonio breast cancer symposiumPerlmutter cancer center

Sacituzumab Govitecan Effective in Black mTNBC Patients

Black women with metastatic triple-negative breast cancer have outcomes comparable to those of the overall patient population, shows a prespecified analysis of ASCENT.

United statesSan antonioChapel hillGenentech rocheLisaa careyJenniferk littonLineberger comprehensive cancer centerGilead sciencesUniversity of texas md anderson cancer centerDrug administrationSan antonio breast cancer symposiumMarilyn jacobs preyer distinguished professorBreast cancer researchComprehensive cancer centerCancer centerBreast cancer

Can Genomic Tests Flag Node-Positive Breast Cancer Pts Who Can Skip Chemo?

Following is a transcript of their remarks: Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year s San Antonio Breast Cancer meeting. I m Hope Rugo, professor of medicine at the University of California San Francisco s Comprehensive Cancer Center, and I m joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco s Comprehensive Cancer Center. Thanks for joining me today. Now, we re going to talk about a really interesting set of presentations at San Antonio that I think really do have direct implications for clinical practice on Monday and this is the use of genomic tests and in some of the studies, Ki67 in order to try and inform us about how to treat our patients who have higher risk node-positive disease.

San antonioUnited statesWest germanKevin kalinskyJo chienJennifer littonCynthia maGreg laubJenniferk littonA jo chienGerman study groupMd anderson cancer centerMedpage todaySan antonio breast cancerPositive breastEmerging novel therapies presented